Cancer gene therapy - Cell Genesys/EntreMedAlternative Names: Angiogenesis inhibitor gene therapy - Cell Genesys/EntreMed; Angiostatin/endostatin gene therapy - Cell Genesys/EntreMed
Latest Information Update: 13 Aug 2003
At a glance
- Originator Cell Genesys; EntreMed
- Class Antineoplastics; Gene therapies
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer